Diligence memo · auto-generated · as of July 2, 2026
Immunic, Inc.
Immunic, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Immunic, Inc. operates in Biotechnology, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immunic, Inc. has raised $514M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $200M on 2026-02-17.
Most recent recorded round closed around 2026-02-17.
Valuation (modeled)modeled
Provath models Immunic, Inc. at approximately $1.3B (range $907M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.45× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era. Within the normal band (145% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 4 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4291 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.